top of page
​BioFinland Member

BioFinland Member

Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd
Company name

Faron Pharmaceuticals Ltd


Joukahaisenkatu 6, FI-20520 Turku


+358 2 469 5151





Contact person

Virve Nurmi


Dr. Markku Jalkanen

Main categories

Drug Discovery and Development / Drug Delivery

Last updated

21 February 2022

Company profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration.

Bexmarilimab, a novel anti-Clever-1 humanized antibody, is a precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Faron is based in Turku, Finland. Further information is available at

bottom of page